Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)

ClinicalTrials.gov ID: NCT00662116

Public ClinicalTrials.gov record NCT00662116. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure

Study identification

NCT ID: NCT00662116
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Synvista Therapeutics, Inc; Industry
Enrollment: 160 participants

Conditions and interventions

Conditions

Diastolic Heart Failure

Interventions

alagebrium Drug
placebo Drug

Drug

Eligibility (public fields only)

Age range: 50 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 29, 2008
Primary completion: Sep 30, 2009
Completion: Nov 30, 2009
Last update posted: Jan 29, 2009

2008 – 2009

United States locations

U.S. sites: 30
U.S. states: 18
U.S. cities: 30

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35294	—
Not listed	Huntsville	Alabama	35801	—
Not listed	Mobile	Alabama	36608	—
Not listed	Anaheim	California	—	—
Not listed	Bakersfield	California	93308	—
Not listed	La Jolla	California	92037	—
Not listed	Roseville	California	95661	—
Not listed	Jacksonville	Florida	32209	—
Not listed	Miami	Florida	33136	—
Not listed	St. Petersburg	Florida	33709	—
Not listed	Covington	Georgia	30014	—
Not listed	Indianapolis	Indiana	46260	—
Not listed	Louisville	Kentucky	40207	—
Not listed	Auburn	Maine	04210	—
Not listed	South Portland	Maine	04106	—
Not listed	Ayer	Massachusetts	01432	—
Not listed	Lincoln	Nebraska	68506	—
Not listed	Ridgewood	New Jersey	07450	—
Not listed	Albany	New York	12205	—
Not listed	Stony Brook	New York	11794	—
Not listed	Winston-Salem	North Carolina	27157	—
Not listed	Cincinnati	Ohio	45219	—
Not listed	Dayton	Ohio	45414	—
Not listed	Fairfield	Ohio	45014	—
Not listed	Sandusky	Ohio	44870	—
Not listed	Oklahoma City	Oklahoma	73112	—
Not listed	Charleston	South Carolina	29401	—
Not listed	Germantown	Tennessee	38138	—
Not listed	Lackland Airforce Base	Texas	—	—
Not listed	Milwaukee	Wisconsin	53215	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00662116, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 29, 2009 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00662116 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →